Low-dose immunotherapy trials reveal systemic barriers to global cancer care access
Original framing: “Ultra-low doses could bring costly cancer treatments to more patients in poorer countries” — STAT News
Scientific evidence supports the efficacy of low-dose immunotherapies in extending survival for certain cancers, but more long-term studies are needed to assess safety and effectiveness across diverse populations and healthcare settings.
The systemic challenge of global cancer care access is rooted in the intersection of corporate power, intellectual property laws, and unequal health systems.
Low-dose immunotherapies offer a potential pathway, but without structural reform—such as global health treaties, open-source drug development, and community-based care models—these treatments will remain out of reach for many. Historical parallels, such as the HIV/AIDS crisis, demonstrate the urgent need for policy change. By integrating indigenous and cross-cultural health practices, and centering the voices of marginalized patients, we can move toward a more just and equitable global health system.